Difference between revisions of "Abciximab"

(Creation of page)
 
(References)
Line 78: Line 78:
  
 
==References==
 
==References==
 +
*Aguirre FV, Topol EJ, and Ferguson JJ, “Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Intergrin in Patients Undergoing Percutaneous Coronary Intervention. EPIC Investigators,” Circulation, 1995, 91(12):2882-90. [PubMed 7796496]
 +
*Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014;64(24):2713-2714]. J Am Coll Cardiol. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017. [PubMed 25260718
 +
*Antman EM, Giugliano RP, Gibson CM, et al, “Abciximab Facilitates the Rate and Extent of Thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. The TIMI 14 Investigators,” Circulation, 1999, 99(21):2720-32. [PubMed 10351964]
 +
*“ASSENT-3 Investigators. Efficacy and Safety of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: The ASSENT-3 Randomised Trial in Acute Myocardial Infarction,” Lancet, 2001, 358 (9282):605-13. [PubMed 11530146]
 +
 
<references/>
 
<references/>
  
 
[[Category:Pharmacology]]
 
[[Category:Pharmacology]]

Revision as of 15:28, 6 June 2019

Administration

  • Type: Glycoprotein IIB/IIIA inhibitor
  • Dosage Forms: Injection
  • Routes of Administration: IV
  • Common Trade Names: Reopro

Adult Dosing

PCI Adjunct

  • 0.125 mcg/kg/min IV x 12h

Unstable angina, refractory

  • 10 mcg/min IV x 18-24h

Pediatric Dosing

Safety/efficacy not established in pediatric patients

Special Populations

Pregnancy Rating

  • Benefits outweigh risks during pregnancy
  • Inadequate human data available to assess risk
  • Risk of maternal hemorrhage during delivery

Lactation risk

  • May use while breast feeding

Renal Dosing

  • Adult: Not defined
  • Pediatric: Unavailable

Hepatic Dosing

  • Adult: Not defined
  • Pediatric: Unavailable

Contraindications

  • Allergy to class/drug
  • Hypersensitivity to murine proteins
  • Active internal bleeding
  • GI/GU bleeding w/in 6 weeks
  • Stroke w/in 2 years
  • Coagulation disorder
  • Plt < 100,000
  • INR > 1.2
  • Recent surgery or trauma
  • HTN, uncontrolled
  • Intracranial neoplasm, AVM, or aneurysm
  • Vasculitis hx
  • Dextran use in coronary procedure

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: <10 min initially then 30 min second phase
  • Metabolism: Other
  • Excretion: Urine

Mechanism of Action

Binds to platelet glycoprotein IIb/IIIa receptors, reducing platelet aggregation

Comments

See Also

References

  • Aguirre FV, Topol EJ, and Ferguson JJ, “Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Intergrin in Patients Undergoing Percutaneous Coronary Intervention. EPIC Investigators,” Circulation, 1995, 91(12):2882-90. [PubMed 7796496]
  • Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014;64(24):2713-2714]. J Am Coll Cardiol. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017. [PubMed 25260718
  • Antman EM, Giugliano RP, Gibson CM, et al, “Abciximab Facilitates the Rate and Extent of Thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. The TIMI 14 Investigators,” Circulation, 1999, 99(21):2720-32. [PubMed 10351964]
  • “ASSENT-3 Investigators. Efficacy and Safety of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: The ASSENT-3 Randomised Trial in Acute Myocardial Infarction,” Lancet, 2001, 358 (9282):605-13. [PubMed 11530146]